PDF icon PDF herunterladen
Open Access
CC BY 4.0 · TH Open 2022; 06(01): e70-e79
DOI: 10.1055/s-0042-1744185
Original Article

COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection

Swati Sharma
1   Deptartment of Biotechnology, Jamia Millia Islamia, New Delhi, India
,
Aastha Mishra
2   CSIR-Institute of Genomics and Integrative Biology, Delhi, India
,
Zahid Ashraf
1   Deptartment of Biotechnology, Jamia Millia Islamia, New Delhi, India
› Institutsangaben
Funding Ministry of Ayush, Government of India: S-14013/2018.
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may result in an overactive coagulative system, thereby resulting in serious cardiovascular consequences in critically affected patients. The respiratory tract is a primary target for COVID-19 infection, which is manifested as acute lung injury in the most severe form of the viral infection, leading to respiratory failure. A proportion of infected patients may progress to serious systemic disease including dysfunction of multiple organs, acute respiratory distress syndrome (ARDS), and coagulation abnormalities, all of which are associated with increased mortality, additionally depending on age and compromised immunity. Coagulation abnormalities associated with COVID-19 mimic other systemic coagulopathies otherwise involved in other severe infections, such as disseminated intravascular coagulation (DIC) and may be termed COVID-19 induced coagulopathy (CIC). There is substantial evidence that patients with severe COVID-19 exhibiting CIC can develop venous and arterial thromboembolic complications. In the initial stages of CIC, significant elevation of D-dimer and fibrin/fibrinogen degradation products is observed. Alteration in prothrombin time, activated partial thromboplastin time, and platelet counts are less common in the early phase of the disease. In patients admitted to intensive care units (ICUs), coagulation test screening involving the measurement of D-dimer and fibrinogen levels, has been recommended. Prior established protocols for thromboembolic prophylaxis are also followed for CIC, including the use of heparin and other standard supportive care measures. In the present review, we summarize the characteristics of CIC and its implications for thrombosis, clinical findings of coagulation parameters in SARS-CoV-2 infected patients with incidences of thromboembolic events and plausible therapeutic measures.

Keywords

covid-19 - coagulopathy - thrombosis - inflammation


Publikationsverlauf

Eingereicht: 29. Oktober 2021

Angenommen: 18. November 2021

Artikel online veröffentlicht:
10. März 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany